CSL (CSL) Stock Price, Fundamentals & Analysis

What CSL does

CSL (CSL) is a stock listed on the ASX in the Healthcare sector, specifically the Biotechnology industry. Headquartered in Melbourne, Australia, it employs 29,000 people and operates through three segments: CSL Behring (plasma products, gene therapies, and recombinants), CSL Seqirus (influenza vaccines and pandemic services), and CSL Vifor (iron deficiency and nephrology products). The company researches, develops, manufactures, markets, and distributes biopharmaceutical products and vaccines internationally, and it also licenses its intellectual property. In the broader Australian healthcare landscape, peers include Fisher & Paykel Healthcare (FPH), Cochlear (COH), Pro Medicus (PME), Telix Pharmaceuticals (TLX), EBOS Group (EBO), Sonic Healthcare (SHL), and Ramsay Health Care (RHC).

Key numbers explained

• 176,95 AUD is the current share price, representing the cost to buy one unit of ownership in the company today.
• -1.21% is the price change today, showing the percentage movement in the share price over the current trading session.
• 84.92 mld. AUD is the market capitalisation, calculated by multiplying the share price by the total number of shares outstanding and used to gauge the company's overall size.
• The forward P/E ratio of 18.7 divides the share price by expected future earnings, helping investors assess whether the stock is priced relative to anticipated profit growth.
• The dividend yield of 2.29% is the annual dividend payment expressed as a percentage of the share price, indicating the cash return shareholders receive relative to the stock's cost.
• The ex-dividend date of 9 sept. 2026 is the cutoff day; buying before this date qualifies an investor for the upcoming dividend payment.
• 45% is the share of earnings paid out as dividends, showing what portion of the company's profit is returned to shareholders rather than retained for reinvestment.
• 0.13 is the beta, a measure of the stock's volatility relative to the broader market, with values below 1 suggesting lower sensitivity to market swings.
• The 52-week range of 90 – 222,47 shows the lowest and highest share prices over the past year, providing context for the current price level.
• -11.1% is the price change over the last 52 weeks, reflecting the total return from one year ago to the present.
• 15.8 mld. USD is the trailing 12-month revenue, representing the total income from sales over the most recent twelve months.
• 5.5% is the year-over-year revenue growth, indicating the percentage increase in sales compared with the same period a year earlier.
• -16.3% is the profit margin, showing that the company operated at a net loss as a percentage of revenue over the trailing twelve months.
• 21.5% is the operating margin, reflecting the percentage of revenue remaining after covering operating expenses but before interest and taxes.
• -15.8% is the return on equity, measuring the net loss generated relative to shareholders' equity over the trailing twelve months.
• 66.8% is the debt-to-equity ratio, expressing the proportion of debt financing relative to equity and used to assess financial leverage.
• 4.03 is the price-to-book ratio, comparing the share price to the company's book value per share.
• -7.51 USD is the trailing 12-month earnings per share, representing the net loss allocated to each outstanding share.
• The next earnings date of 17 aug. 2026 is the scheduled release date for the company's upcoming financial results.

What to watch

Investors tracking CSL may monitor factors common to large-cap biotechnology and healthcare stocks. Earnings reports, such as the one scheduled for 17 aug. 2026, often drive price movements as they update expectations for revenue and profitability. Dividend policy changes are relevant given the 2.29% yield and the 45% payout ratio, which together show how much of earnings flow to shareholders. The company's exposure to multiple countries and therapeutic areas can make it sensitive to regulatory decisions, public health developments, and currency fluctuations. Broader market conditions and sector rotation also influence biotechnology stocks, as does the company's leverage, reflected in the 66.8% debt-to-equity ratio.